1. Scrip
  2. >>Leadership

Pharma Not-For-Profit Projects Can Only Improve Reputation

Increased Focus on Planet, Not Just Pills

 
• By Kevin Grogan

Sanofi is the latest drugmaker to announce a major initiative aimed at improving access to medicines in poorer countries, the type of move that should continue to lift the reputation of big pharma above the likes of big oil and big tobacco.

Paul Hudson
Sanofi CEO Paul Hudson taking social responsibility seriously • Source: Sanofi

Big pharma’s reputation with the public seems to have risen given its leading role in tackling the pandemic but beyond COVID-19, drugmakers will be hoping their efforts in tackling pressing issues such as healthcare inequalities and climate change can build on that goodwill.

The latest example of walking the walk in terms of corporate social responsibility (CSR) is Sanofi‘s decision to form...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By Kevin Grogan

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Pharming’s New CEO On Plans To Take Rare Disease Firm To Next Level

 
• By Kevin Grogan

Fabrice Chouraqui is full of praise for the ‘amazing platform for growth’ established by predecessor Sijmen de Vries, which has left the Dutch firm poised to reap the rewards of its self-financing model.

Executives On The Move: Three New CEOs And Five New CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Vyome Holdings, CoRegen and Resolution Therapeutics, plus Takeda hires Rhonda Pacheco from Eli Lilly as the President of its US unit.

Takeda APAC Head On ‘Conscious’ Pricing, Qdenga And Reverse Digital Mentoring

 
• By Anju Ghangurde

Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.

More from Therapy Areas

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

 
• By Manas Mishra

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

 
• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.